News
Highlighted news
March 2023: Dupilumab improves hand, foot atopic dermatitis in phase 3 study
Research results show patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile in phase 3 study results.
Sept. 2021: FDA approves topical ruxolitinib for atopic dermatitis, first JAK inhibitor for this indication in the U.S.
The first topical JAK inhibitor approved for AD for mild to moderate atopic dermatitis ages 12 years and older– and the first JAK inhibitor approved for this indication – in the United States.
Apr. 2021: Webinar: JAK inhibitors for treating eczema
What are JAK inhibitors and how can they improve the treatment of eczema? Dr. Eric Simpson explains everything the eczema community needs to know about this new class of medications.
May 2021: Topical Steroid Withdrawal (TSW): What the Eczema Community Needs to Know, Now
Examining the poorly understood but potentially debilitating side effect of topic steroid use, Topical Steroid Withdrawal (TSW)
Feb. 2021: Outcome Measures for Atopic Eczema Trials Determined at Latest HOME Meeting
Defining consensus outcome measures for atopic dermatitis (Harmonizing Outcome Measures for Eczema (HOME))
Feb. 2021: Investigators Take Global Look at Best-Practice AD Care
Several universal gaps in diagnosis and treatment of atopic dermatitis (AD) as well as real-world interventions for improvement are the focus of a ground-breaking report.
Jan. 2020: Rash Decisions; How to Deal with Itchy, Red Skin
National Institutes of Health Article on how to deal with itchy, red skin.
Jul. 2020: Abrocitinib for atopic dermatitis: a step forward
Article published in the Lancet on study drug Abrocitinib (oral treatment) for the treatment of atopic dermatitis.
Oct. 2016: Targeted drug tames atopic eczema in Phase III trials
Study results published in the New England Journal of Medicine show the potential of dupilumab in treating a common, but for some disabling, chronic skin condition for which no current treatments are effective.
Oct. 2016: New Drug for Severe Eczema Is Successful in 2 New Trials
Examining results of Phase III trials for study drug Dupilumab in treating severe eczema.
Non-OHSU news
Highlighted eczema news stories related to non-OHSU faculty
Dec. 2021: Breaking news: FDA approves Adbry™ (tralokinumab-ldrm)
Adbry™ (tralokinumab-ldrm), a biologic medication for adults (18+) with moderate to severe atopic dermatitis (AD) for whom topical prescription treatments have not adequately worked or are not advised, has been approved by the U.S. Food and Drug Administration (FDA)
Sept. 2021: Latest News on Atopic Dermatitis in Children
At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.